Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 15/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596148 | 1.00 | CACNA1H (0.54) | CACNA1HCYP3A4KITHTTSMN1; SMN2 | |
| SCHEMBL8225683 | 0.91 | CACNA1H (0.47) | CACNA1HCYP3A4KITHTT | |
| SCHEMBL8224566 | 0.91 | CACNA1H (0.47) | CACNA1HCYP3A4KIT | |
| SCHEMBL8224856 | 0.91 | CACNA1H (0.47) | CACNA1HCYP3A4KIT | |
| SCHEMBL12876968 | 0.85 | CACNA1H (0.75) | CACNA1H | |
| SCHEMBL8212491 | 0.76 | CACNA1H (0.55) | CACNA1HCYP3A4KIT | |
| SCHEMBL12877046 | 0.75 | CACNA1H (0.62) | CACNA1HCYP3A4 | |
| SCHEMBL12877049 | 0.74 | CACNA1H (0.53) | CACNA1HCYP3A4 | |
| SCHEMBL8213093 | 0.74 | CACNA1H (0.53) | CACNA1HCYP3A4 | |
| SCHEMBL13596146 | 0.74 | CACNA1H (0.65) | CACNA1HKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | CACNA1H 1192/4885CYP3A4 169/4885KIT 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.